01
Cash & equivalents increased 4.2%
Cash & equivalents changed +4.2% from the comparable as-filed period.
$10.9M→$11.3MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTEntera Bio Ltd.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +4.2% from the comparable as-filed period.
Gross profit changed +0.0% from the comparable as-filed period.
Net income changed -175.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ENTX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001178913-26-004178SEC ↗4Aug 7, 2026Period Aug 7, 20260001178913-26-003957SEC ↗4Aug 7, 2026Period Aug 7, 20260001178913-26-003956SEC ↗4Aug 7, 2026Period Aug 7, 20260001178913-26-003955SEC ↗4Aug 7, 2026Period Aug 7, 20260001178913-26-003954SEC ↗4Aug 7, 2026Period Aug 7, 20260001178913-26-003953SEC ↗4Aug 7, 2026Period Aug 7, 20260001178913-26-003952SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 7, 2026Filed Aug 7, 2026 | Rubin Steven DDirector | Grant Or AwardDirect | 19,117 | $0 | $0 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 7, 2026 | Rubin Steven DDirector | Grant Or AwardDirect | 33,368 | $0 | $0 | Form 4 ↗ |
| Aug 7, 2026Filed Aug 7, 2026 | Rubin Steven DDirector | Grant Or AwardDirect | 43,405 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -71.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Research & development changed +110.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Revenue changed +0.0% from the comparable as-filed period.
Selling, general & administrative changed +20.4% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001178913-26-003951